NovaBridge Reports Positive Phase 2a Results for VIS-101 in Wet AMD

NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

NovaBridge Reports Positive Phase 2a Results for VIS-101 in Wet AMD

Key Takeaways NovaBridge Biosciences reported positive phase 2a topline results for VIS-101, a dual VEGF-A and ANG-2 inhibitor being developed for retinal vascular diseases including wet AMD The therapy demonstrated significant visual acuity improvements, reductions in retinal thickness, and promising durability The company plans to initiate a dose-finding phase 2b study in the second half of 2026, with a global phase 3 program expected …